Figure 5
Figure 5. Suppression of IFN-γ production by CD4+GFP(Foxp3)+ Tregs with or without OX40 stimulation. (A) CD4+GFP(Foxp3)− T effector cells sorted from OX40KO foxp3gfpKI mice were stimulated with anti-CD3 plus wt APCs or OX40Ltg APCs, IFN-γ production by the T effector cells in the presence or absence of wt CD4+GFP(Foxp3)+ Tregs was analyzed by ELISPOT assay. Data shown are mean (± SD) of 3 experiments. (B) OX40 deficient CD4+GFP(Foxp3)− T effector cells were stimulated with anti-CD3 plus OX40Ltg APCs. In these cultures, wt or OX40 deficient CD4+GFP(Foxp3)+ Tregs were added as indicated, and suppression of IFN-γ production was shown. Data shown are mean (± SD) of 3 independent experiments. (C) CD4+GFP(Foxp3)− T effector cells from OX40KO foxp3gfpKI mice were transferred into syngeneic Rag−/− hosts (5 × 105 cells/mouse), groups of host mice were also transferred with equal number of wt CD4+GFP(Foxp3)+ Tregs. The host mice were then grafted with DBA/2 skin grafts and treated with an agonist anti-OX40 mAb, and skin allograft survival was shown. (*) P < .05

Suppression of IFN-γ production by CD4+GFP(Foxp3)+ Tregs with or without OX40 stimulation. (A) CD4+GFP(Foxp3) T effector cells sorted from OX40KO foxp3gfpKI mice were stimulated with anti-CD3 plus wt APCs or OX40Ltg APCs, IFN-γ production by the T effector cells in the presence or absence of wt CD4+GFP(Foxp3)+ Tregs was analyzed by ELISPOT assay. Data shown are mean (± SD) of 3 experiments. (B) OX40 deficient CD4+GFP(Foxp3) T effector cells were stimulated with anti-CD3 plus OX40Ltg APCs. In these cultures, wt or OX40 deficient CD4+GFP(Foxp3)+ Tregs were added as indicated, and suppression of IFN-γ production was shown. Data shown are mean (± SD) of 3 independent experiments. (C) CD4+GFP(Foxp3) T effector cells from OX40KO foxp3gfpKI mice were transferred into syngeneic Rag−/− hosts (5 × 105 cells/mouse), groups of host mice were also transferred with equal number of wt CD4+GFP(Foxp3)+ Tregs. The host mice were then grafted with DBA/2 skin grafts and treated with an agonist anti-OX40 mAb, and skin allograft survival was shown. (*) P < .05

Close Modal

or Create an Account

Close Modal
Close Modal